Oncology Business Management

With a March 31 deadline looming for the 114th Congress to either patch or repeal the sustainable growth rate (SGR) formula, the Health Subcommittee of the US House of Representatives' Energy and Commerce Committee will hold a hearing to discuss the future of the fundamentally flawed formula used to set Medicare physician payments.

No one biomarker is effective for all types of bladder cancer, says Michael Cookson, MD, a professor and chairman of the Department of Urology at the University of Oklahoma College of Medicine.

OncLive® and Stephenson Cancer Center, the only comprehensive academic cancer center in Oklahoma, have become partners in raising the standard of cancer care through OncLive's Strategic Alliance Partnership program, OncLive announced.

The FDA's calendar for making decisions on new oncology drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.

In a 14-0 vote, the FDA's ODAC unanimously recommended approval of EP2006, a biosimilar version of filgrastim. If the FDA follows the recommendation, the drug would become the first biosimilar approved in the United States.

With the FDA approval of several oral chemotherapy agents, the cost of medications to treat cancer is increasing rapidly. To control costs, legislators, patient advocates, and physicians have pushed for oral chemotherapy parity laws.

Sweeping changes to the way America delivers care at the end of life would better serve patients and their families, while achieving the goals sought in the Affordable Care Act (ACA) of better health, cost savings, and especially patient satisfaction

It's not uncommon for a business to use a superlative in its name, but Premier Medical Group in Poughkeepsie, NY, truly lives up to its moniker.

It is always fun to try to predict the future. Invariably you will be wrong.

Urologists who are members of LUGPA are doing the right thing by being part of large group practices.

The FDA has approved the PD-1 inhibitor nivolumab for patients with unresectable or metastatic melanoma following treatment with ipilimumab or a BRAF inhibitor.

Only 10% of current medical students aspire to open up shop as a solo practitioner-a 50% drop since 2008. Last year, 17% of students surveyed said that solo practice was a consideration. On the other hand, those students who anticipate seeking employment with a large group practice or hospital has risen to 73%, as compared with 70% last year.

The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer.

Several initiatives that have a dramatic impact on healthcare today were born during that time–managed care, transitioning away from inpatient care toward outpatient care, and the introduction of clinical pathways.

While Laszewski said the Affordable Care Act (ACA), which is driving many of the changes, may end up being altered, he doesn't expect the program to be disbanded due to the political shift in legislative power.

The FDA has approved lanreotide for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.